NVS - Cell and gene therapy market to reach $80B by 2029: report
2023-12-29 17:15:31 ET
More on bluebird bio, CRISPR Therapeutics, etc.
- bluebird bio's Lyfgenia: Navigating Commercialization Challenges In SCD
- Vertex's Pain Game: VX-548 Takes Aim At Neuropathic Battles
- Vertex And CRISPR Therapeutics: Historic Exa-cel Approval, Why Market Is Nonplussed
- CRISPR chief medical officer resigns, stepping down Jan. 26
- bluebird bio stock slides on pricing of $125 million stock offering
For further details see:
Cell and gene therapy market to reach $80B by 2029: report